A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)

Completed · Phase 1

Conditions studied: Parenteral Nutrition

In brief

This is a phase 1, prospective, single-center, randomized sequence, double-blind, 2-way crossover, relative bioavailability study in healthy adult subjects comparing Sodium Glycerophosphate Injection (SGP) to Sodium Phosphate Injection (NaP). In this study it is planned to randomize approximately 42 healthy male and female subjects. All study periods will be completed during a single residency, the overall duration of residency will be 11 days (10 nights).

Key facts

Study ID

NCT06842121

Run by

Baxter Healthcare Corporation

People needed

42

Starts

2025-01-27

Expected to finish

2025-05-22

Last updated by the study team

2025-06-29

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males or non-pregnant, non-lactating healthy females.
• Aged 18 to 55 years, inclusive, at the time of signing informed consent.
• Body mass index (BMI) of 18.5 to 29.9 kg/m\^2 and a minimum body weight of 57 kg as measured at screening.
• Must be willing and able to comply with all study requirements including dietary requirements.
• Subject must be literate, has signed a written informed consent form (ICF) and has the ability to communicate and comply with all study requirements
• Must agree to use an adequate method of contraception.
• Alkaline phosphatase level within standard reference range/normal limits at screening and admission.
• Serum inorganic phosphate level within standard reference range/normal limits at screening and admission.
• Serum parathyroid hormone (PTH) level within standard reference range/normal limits at screening.
• Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels within reference range/normal limits at screening and admission.

You may not qualify if…

• Subjects who have received any investigational medicinal product (IMP) in a clinical research study within 5 half-lives or within 30 days prior to first dose, whichever is longer.
• Subjects who are study site or Sponsor employees, or subjects who are immediate family members of study site or Sponsor employees.
• Subjects who have previously been administered IMP in this study.
• History of any drug or alcohol abuse in the past 2 years prior to screening.
• Regular alcohol consumption in 6 months prior to screening.
• A confirmed positive alcohol urine test at screening or admission.
• Current smokers or those who have smoked within the last 12 months prior to screening. A confirmed positive urine cotinine test at screening or first admission.
• Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months prior to screening.
• Females of childbearing potential must have a negative pregnancy test (urine pregnancy test at screening). Females who are pregnant or lactating will be excluded.
• Have poor venous access that limits phlebotomy.
• Clinically significant abnormal clinical chemistry or hematology as judged by the Investigator.
• Clinically significant abnormal urinalysis as judged by the Investigator.
• History of diabetes mellitus (types I or II).
• Prediabetes (fasting blood sugar level of >106 (repeat x 1 for confirmation of abnormal level).
• Hypertriglyceridemia (fasting triglyceride level of > 200 mg/dL) at screening.
• Subjects who, in the Investigator's opinion, have a clinically significant abnormal 12-lead resting ECG.
• Positive drugs of abuse test result.
• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results.
• Evidence of renal impairment at screening, as indicated by an eGFR < 90mL/min/m\^2.
• History of any active systemic or immunologic disease, including but not limited to active renal, hepatic, hematological, gastrointestinal (except appendectomies/cholecystectomy), endocrinal, pulmonary (including asthma), cardiovascular, neurologic, or neurological disease (including demyelinating diseases such as multiple sclerosis), hypertension, tuberculosis, or systemic fungal infection.
• History of bleeding ulcer, bleeding abnormalities or coagulation abnormalities.
• History of hypophosphatasia.
• Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients.
• Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hay fever is allowed unless it is active.
• Significant serious active skin disease, including rash, food allergy, eczema, psoriasis, or urticaria.

Where it is running

• Austin PPD CRU — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.